Astellas Pharma Logo
JP3942400007
856273
ALPMF

Astellas Pharma

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet


  • Astellas starts phase-3 study of ASP2138 in gastric cancer

    Astellas treated the first patient in a randomized, double-blind phase‑3 study of ASP2138 in combination with chemotherapy and pembrolizumab in adult patients with locally advanced, inoperable or metastatic CLDN18.2‑positive, HER2‑negative gastric cancer or gastroesophageal junction adenocarcinoma. ASP2138 is a subcutaneously administered bispecific antibody that binds CLDN18.2 on tumor cells and CD3 on T cells to activate antitumor immune responses. The study (570 participants, multiple countries) is placebo-controlled and has overall survival and progression-free survival as its primary endpoints. Safety and efficacy have not yet been proven; the study supports Astellas' goal to start multiple phase‑3 or registration‑enabling studies by fiscal year 2027. » Mere på de.investing.com


  • Astellas Pharma pays 78 JPY dividend for 2026, payout rises 5.41%

    Astellas Pharma resolved at the annual general meeting to pay a dividend of 78.00 JPY for 2026; the total payout amounts to 136.10 billion JPY, 5.51% higher than the previous year. The dividend yield for 2026 is 3.10% (previous year 5.12%). The stock closed at 2,145.50 JPY on the AGM day and is trading ex-dividend; the one-year total return (price + dividend) is 58.16%. Analysts expect an increase to 80.55 JPY for 2027, which would lift the yield to around 3.75%. » Mere på finanzen.net


  • Astellas Pharma stock falls after presentation of growth strategy CSP2026

    Astellas Pharma’s stock fell 1.5% to close at 2,233.5 yen after the company unveiled its five‑year plan CSP2026. The plan includes more than 10 phase‑3 or approval‑relevant studies through fiscal 2030, cumulative core operating profit before R&D of over 4.3 trillion yen, and a doubling of sales from strategic brands. Investors reacted with a classic “sell‑the‑news” dynamic, amplified by concerns over sales declines for Xtandi due to patent expiries and a mid‑term consensus expecting annual declines in revenue and profit. Despite record sales of 2,139.2 billion yen for 2025, sentiment remains subdued given uncertain medium‑term prospects. » Mere på de.investing.com


  • Astellas reports record sales and strong profit rise, shares fall over IRA and patent risks

    In fiscal 2025 Astellas posted sales above ¥2.1 trillion for the first time (¥2,139.2 billion) and increased core operating profit by 41.6% to ¥555.7 billion; net profit rose to ¥291.6 billion. Growth was driven mainly by strategic brands such as PADCEV, IZERVAY and VYLOY, while the pipeline reported several proof-of-concept successes and the SMT cost-reduction program improved margins. The stock fell 3.34% after the results as investors worried about the effects of the US Inflation Reduction Act, upcoming patent expiries for Xtandi and a weakened sales forecast for 2026. » Mere på de.investing.com


  • Astellas Pharma reports strong Q3 2025: revenue and operating profit rise sharply

    Astellas Pharma posted Q3 2025 revenue of ¥1,601.3 billion (+10.2%) and core operating profit of ¥442.1 billion (+48.6%). The company raised its full-year revenue forecast by ¥70 billion and said it will lift its core operating profit forecast by ¥30 billion. Shares rose 1.1% in after-hours trading following the results. Astellas outlined plans for several Phase‑3 studies, is targeting a 30% operating margin by FY2027, and warned of risks from the upcoming patent expiry of XTANDI. » Mere på de.investing.com

I 2026 har Astellas Pharma allerede udloddet 0,21 € i udbytte. Den seneste udlodning fandt sted i juni.

Virksomhedstal

I det seneste kvartal havde Astellas Pharma en omsætning på 3,53 mia. € og et nettoresultat på 560,34 mio. €

(EUR) september 2026
YoY
Omsætning 3,53 mia. 16,93 %
Bruttofortjeneste 2,63 mia. 18,27 %
Nettoresultat 560,34 mio. 22,86 %
EBITDA 1,22 mia. 37,20 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
28,36 mia. €
Antal aktier
1,79 mia.
Højeste/laveste i 52 uger
16,09 € - 11,14 €
Udbytteafkast
2,74 %
Udbytte TTM
0,43 €
Næste udbytte
0,23 €
Beta
0,09
P/E (PE Ratio)
12,79
PEG (PEG Ratio)
0,06
K/I (PB Ratio)
2,49
P/S (PS Ratio)
2,07

Virksomhedsprofil

Astellas Pharma Inc. beskæftiger sig med fremstilling, markedsføring, import og eksport af lægemidler på verdensplan. Virksomheden leverer XTANDI, en androgenreceptor-signalhæmmer til prostatakræft; XOSPATA, en FLT3-hæmmer til voksne patienter med recidiverende eller refraktær akut myeloid leukæmi med en FLT3-mutation; PADCEV, en behandlingsløsning til voksne patienter med lokalt fremskreden eller metastatisk urotelkræft; Betanis/Myrbetriq/BETMIGA, en beta-3-adrenerg receptoragonist til behandling af urgency, urinhyppighed og urge-inkontinens; Evrenzo, en oral behandling af anæmi forbundet med kronisk nyresygdom; samt Prograf og Advagraf/Graceptor/ASTAGRAF, som er immunsuppressiva, der anvendes til at undertrykke organafstødning efter en transplantation. Virksomheden tilbyder desuden mirabegron til behandling af neurogen detrusoroveraktivitet hos pædiatriske patienter; Vesicare til behandling af OAB; Eligard til behandling af prostatakræft; Harnal/Omnic til behandling af benign prostatahyperplasi; og Funguard/MYCAMINE, et antifungalt middel. Virksomheden har et klinisk forsøgssamarbejde med Merck & Co., Inc.; CytomX Therapeutics, Inc.; og en aftale med BANDAI NAMCO Entertainment Inc. om udvikling af en smartphone-applikation til støtte for træning. Den har også en strategisk forskningsalliance med Harvard University om forskning og udvikling af terapier og teknologier af gensidig interesse; et forskningssamarbejde med Actinium Pharmaceuticals, Inc. om udvikling af målrettede radioterapier ved hjælp af deres Antibody Warhead Enabling-teknologiplatform samt en aftale med Zenith Epigenetics Ltd. om evaluering af ZEN-3694; og et samarbejdsaftale med Cytokinetics, Incorporated. Virksomheden har en strategisk samarbejds- og licensaftale med Minovia Therapeutics Ltd. om forskning, udvikling og kommercialisering af celleterapiprogrammer til sygdomme forårsaget af mitokondriel dysfunktion. Astellas Pharma Inc. blev grundlagt i 1923 og har hovedkontor i Tokyo, Japan.

Navn
Astellas Pharma
CEO
Naoki Okamura
Hjemsted Tokyo, ty
Japan
Websted
Sektor
Sundhed
Branche
Lægemidler
Børsnotering
04.01.2000
Medarbejdere 14.099

Tickersymboler

Børs Symbol
Pnk
ALPMF
Japan Exchange Group
4503.T
Frankfurt
YPH.F
Düsseldorf
YPH.DU
München
YPH.MU
🍪

Parqet  bruger cookies. Læs mere